Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 2 5Phase NA 2Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Pleural Effusion, Malignant 1

Interventions

Radiosurgery 6pembrolizumab 5Oncolytic Virotherapy 4Magnetic Resonance Spectroscopy 4Fluorodeoxyglucose F18 4Carboplatin 4Paclitaxel 3Cyclophosphamide 3Cisplatin 3osimertinib 2atezolizumab 2aldesleukin 2Tobacco Use Cessation Devices 2Specimen Handling 2Radiotherapy 2Positron-Emission Tomography 2Pemetrexed 2Nivolumab 2Docetaxel 2toripalimab 1sugemalimab 1sodium thiosulfate 1perflutren 1palbociclib 1icotinib 1gallium 68 PSMA-11 1fludarabine 1durvalumab 1dapagliflozin 1dacomitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Sodium Chloride × Thoracic × Clear all
NCT05565014 2022-10-04

Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion

Hubei Cancer Hospital

Phase EARLY_PHASE1 Unknown
90 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡